Recent review of the medical industry: Mindray Medical launched the A-share listing road

As a domestically-made medical device, Mindray, his every move, whether it is delisted from the United States or listed on the Chinese stock market, has touched the eyes of the industry. Recently, the pre-disclosure information on the website of the China Securities Regulatory Commission showed that Mindray Medical first issued a draft of the public offering prospectus, which is planned to be listed on the Shenzhen Stock Exchange. If this time can be successfully "over the meeting", Mindray Medical will become the first stock of medical equipment with a market value of over 100 billion. In addition, what are the hot spots in the medical industry in the near future? The editor of OFweek Medical Network will take you to review it.

News review

China's largest medical device company Mindray launched A-share listing road

On May 26th, the website of the China Securities Regulatory Commission released the “Prospectus of the initial public offering of Shenzhen Mindray Biomedical Electronics Co., Ltd. (the draft was submitted on May 16, 2017)”, which means that Mindray officially launched the A-share IPO. pace. According to the prospectus, the sponsor institution is BOC International and the joint lead underwriters are BOC International and Huatai United Securities.

According to the prospectus, Mindray has 57 wholly-owned or holding subsidiaries (including direct and indirect subsidiaries), including 18 in China and 39 overseas. In 2016, the company's operating income was 9.031 billion yuan, the largest in China. The medical device sales company, followed by Xinhua Medical and Lepu Medical. As an international company, its overseas sales accounted for half of the total. The proportion in 2014-2016 was 54.91%, 53.72% and 50.00% respectively. [ Original reading ]

Go man-machine war: AlphaGo's next goal will be the medical field?

Recently, Ke Jie, the first person in the world of Go, lost to AlphaGo with a slight disadvantage of a quarter. In the interview, Ke Jie said: "Now its chess has become more and more like the "Go God" I understand. Its understanding and judgment on chess is far better than us."

After the game, Mr. Schmidt, the executive chairman of Alphabet, explained that the reason for AlphaGo and Ke Jie was to see the potential of AlphaGo through Ke Jie. From the actual results, the gap is also very small. Schmidt said that Ke Jie should also learn from AlphaGo's skills, so the next game is still worth looking forward to. [ Original reading ]

Baidu returns to artificial intelligence medical technology: BAT is far from over

As the specific application of Baidu brain in the medical field, Baidu Medical Brain carries out artificial intelligent product design through massive medical data and professional literature collection and analysis, simulates doctors' consultation process, communicates with users in multiple rounds, and proposes according to user's symptoms. Possible problems, repeated verification, and final recommendations. In the process, the patient's symptom descriptions can be collected, summarized, classified, and sorted to remind the doctor of more possibilities and assist the primary doctor to complete the consultation.

In April this year, Baidu Medical Brain announced a partnership with Community 580, which officially claimed to have signed 2,000 urban community health centers, with more than 25,000 family doctors providing services through the platform.

Dr. Fan Wei, head of Baidu Medical Brain Technology, said that the cooperation with the community 580 will further open up the possibility of “artificial intelligence + medical care” and provide intelligent solutions for traditional medical treatment. Baidu medical brain will continue to optimize and improve in actual use, create more new value for patients, doctors and platforms. In the future, it will better promote the national policy of grading medical treatment to the grassroots level and better serve the grassroots patients. Promote the solution of the problem of “difficult medical treatment” for the nationals.” [ Original reading ]

Fosun Pharma's coaching change: increasing investment in medical device innovation in the future

20 days ago, Fosun Pharma released its first quarter 2017 results report, achieving operating income of RMB 3.88 billion, an increase of 20.29% over the same period of the previous year...

A month ago, on March 28, Fosun International released its 2016 results announcement in Hong Kong. Chen Qiyu and Guo Guangchang and several other colleagues accepted an interview with reporters at the Four Seasons Hotel in Hong Kong.

Different from previous years, Chen Qiyu has become the co-president of Fosun Group in addition to being the chairman of Fosun Pharma. Also interviewed by the media was another Xu Xingliang, the new president of Fosun. For the attendance lineup of Fosun Group this year, the external evaluation is "the new generation management has been replaced", and there will be a different Fosun. [ Original reading ]

Calcium Ethoxide CAS No.2914-17-2

Calcium Ethoxide Basic Information
CAS: 2914-17-2
MF: C4H10CaO2
MW: 130.2
EINECS: 220-828-8
Mol File: 2914-17-2.mol
Calcium Ethoxide Chemical Properties
Melting point >170°C (dec.)
Safety Information
Risk Statements 11-14-36

Safety Statements 8-16-26-43

Calcium Ethanoate,Calcium Ethanoate And Ethanol,Calcium Ethanoate Formula,Calcium Ethanoate And Ethanol Reaction,Calcium Ethanoate Balanced Equation,Calcium Ethanoate Bonding

Shandong YingLang Chemical Co.,Ltd , https://www.sdylhgtrade.com